Results of phase Ib/II trial of PEP503 (NBTXR3, radioenhancer) with chemoradiotherapy in patients with rectal cancer.
Sign Up to like & getrecommendations! Published in 2025 at "Nanomedicine"
DOI: 10.1080/17435889.2025.2487411
Abstract: AIM To evaluate the efficacy, recommended phase II dose (RP2D), dose-limiting toxicity (DLT), and safety profiles of PEP503 (NBTXR3) in combination with concurrent chemoradiotherapy (CCRT) in patients with locally advanced or unresectable rectal adenocarcinoma. METHODS… read more here.
Keywords: pep503; chemoradiotherapy; rectal cancer; ccrt ... See more keywords
A phase Ib/II trial of PEP503 (NBTXR3, radioenhancer) with radiotherapy and chemotherapy in patients with rectal cancer.
Sign Up to like & getrecommendations! Published in 2023 at "Nanomedicine"
DOI: 10.2217/nnm-2022-0186
Abstract: Aims: To investigate the safety profile, dose-limiting toxicity and antitumor activity of PEP503 (NBTXR3) nanoparticles with radiotherapy and concurrent chemotherapy in patients with locally advanced or unresectable rectal cancer. Methods: Patients will receive a single… read more here.
Keywords: chemotherapy patients; radiotherapy chemotherapy; phase; pep503 nbtxr3 ... See more keywords